AR and metastatic neoplasm: We observe there are no changes in PARP7 mRNA levels in primary tumors (TCGA-PRAD) compared with normal prostate cells (GTEx prostate), but the expression is reduced in metastatic tumors (17), and the difference is greater for metastatic tumors that are AR+ (Fig. 6A; Supplementary Fig. S6A).